1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer

 
• By Emily Hayes

ESMO data suggest that patients with no expression of PD-L1 who took Tecentriq were able to generate an immune response, a result Genentech believes reflects the particular mechanism of action compared to PD-1 inhibitors like Opdivo and Keytruda.

With additional data from the Phase III OAK trial in hand, Roche has high hopes that the evidence that its PD-L1 inhibitor Tecentriq appears to generate new immunity in patients with no PD-L1 expression will help differentiate the product in the competitive programmed death checkpoint inhibitor space.

The company presented OAK data for Tecentriq (atezolizumab) in second-line NSCLC at the European Society of Medical Oncology annual meeting...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Anticancer

J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

AstraZeneca Stays Coy On US Pricing Deal Impact

 
• By Andrew McConaghie

Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.

Compugen Keeps Faith In AstraZeneca TIGIT Alliance And PVRIG

 
• By Andrew McConaghie

New CEO, Eran Ophir, is banking on positive readouts from AstraZeneca and Arcus’s TIGIT programs soon validating its science as it pushes ahead with its immuno-oncology pipeline in a field littered with disappointments.

Walmsley Signs Off With GSK Growth Upgrade

 
• By Andrew McConaghie

The departing CEO announced improved full-year sales and profit forecasts before handing over to Luke Miels in January; he will then have to deliver on GSK’s upgraded forecast of £40bn revenues in 2031.

More from Therapy Areas

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.